• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Aetna Sees Promise in New Heart Disease Diagnostic

Article

With spending on diagnostics alone for cardiovascular disease likely to be a major challenge for insurers amid the baby boom wave, Aetna is turning to an emerging option as part of a strategy to avoid invasive tests and treatments.

With spending on diagnostics alone for cardiovascular disease likely to be a major challenge for insurers amid the baby boom wave, Aetna is turning to an emerging option as part of a strategy to avoid invasive tests and treatments.

Members of Aetna and its Coventry subsidiary now have access to a gene expression blood test that helps diagnose obstructive coronary artery disease, a condition often investigated with stress testing, electrocardiograms, CT scans, dye-based angiography or catheterizations.

Under Aetna’s new clinical policy, a coronary artery disease (CAD) gene expression test sold by the company CardioDX will be covered as medically necessary for non-diabetic adult members experiencing chest pain or similar symptoms without a history of CAD.

Read the full story here: http://bit.ly/1r8gT8D

Source: Healthcare Payer News

Related Videos
Shrilla Banerjee, MD, FRCP
Donna Fitzsimons
Milind Desai, MD, MBA
Milind Desai
Stephen Nicholls
G.B. John Mancini, MD
Stephen Nicholls, PhD, MBBS
G.B. John Mancini, MD, University of British Columbia
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.